329901

antibody from BioLegend

Targeting: CFP PFC

Immunohistochemistry (Recommended by provider)

Flow cytometry (Data presented on provider website)

Antibody Data

Product number

329901

Provider

BioLegend

Product name

Purified anti-human CD279 (PD-1)

Antibody type

Monoclonal

Antigen

CD279 (PD-1)

Description

The program death 1 (PD-1) receptor CD279 is a 55 kD member of the immunoglobulin superfamily. CD279/PD-1 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279/PD-1 is expressed predominantly on activated T cells, B cells and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279/PD-1 and are members of the B7 gene family. Evidence reported to date suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells.  Interaction of CD279:PD-ligands results in inhibition of T cell proliferation and cytokine secretion.

Reactivity

Human, Simian

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Vial size

25 µg

Concentration

0.5 mg/ml

Storage

The antibody solution should be stored undiluted at 4°C.

References

Submitted references

Dominant clonotypes within HIV-specific T cell responses are programmed death-1high and CD127low and display reduced variant cross-reactivity.

Conrad JA, Ramalingam RK, Smith RM, Barnett L, Lorey SL, Wei J, Simons BC, Sadagopal S, Meyer-Olson D, Kalams SA
Journal of immunology (Baltimore, Md. : 1950) 2011 Jun 15;186(12):6871-85

---

Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7.

Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said EA, Kared H, Grandvaux N, Boulassel MR, Routy JP, Ancuta P
Journal of immunology (Baltimore, Md. : 1950) 2011 Apr 15;186(8):4618-30

---

Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling.

Radziewicz H, Ibegbu CC, Hon H, Bédard N, Bruneau J, Workowski KA, Knechtle SJ, Kirk AD, Larsen CP, Shoukry NH, Grakoui A
Journal of immunology (Baltimore, Md. : 1950) 2010 Mar 1;184(5):2410-22

---

Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.

Vojnov L, Reed JS, Weisgrau KL, Rakasz EG, Loffredo JT, Piaskowski SM, Sacha JB, Kolar HL, Wilson NA, Johnson RP, Watkins DI
Journal of virology 2010 Jan;84(2):753-64

---

Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations.

Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, Gyenes G, Mason RD, Mohamed R, MacDonald KS, Kovacs C, Ostrowski MA
Journal of virology 2009 Sep;83(17):8722-32

---

Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy.

Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY
Journal of immunology (Baltimore, Md. : 1950) 2008 Nov 15;181(10):6707-10

---

Simian immunodeficiency virus (SIV)-specific CD8+ T-cell responses in vervet African green monkeys chronically infected with SIVagm.

Zahn RC, Rett MD, Korioth-Schmitz B, Sun Y, Buzby AP, Goldstein S, Brown CR, Byrum RA, Freeman GJ, Letvin NL, Hirsch VM, Schmitz JE
Journal of virology 2008 Dec;82(23):11577-88